The intrepid New Yorker pulls back the curtain on how private companies profit from taxpayer-funded research.
NIH
Posted inEconomic Policy
Beyond the Planet of the Pharma Bros
A growing insulin crisis adds urgency to efforts to radically reform the prescription drug pipeline.
Posted inMoney, Politics, and Power
Cures Act Is Bad Medicine for NIH, FDA
A bipartisan bill that promises more money for research and development is actually full of giveaways for the pharmaceutical industry and other trade groups.